Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient
The development of monoclonal antibody therapies targeting specific components of the pathways relevant to asthma pathophysiology has revolutionized treatment of severe asthma both in adults and children and helped to further unravel the heterogeneity of this disease. However, the availability of multiple agents, often with overlapping eligibility criteria, creates a need for pragmatic guidance for specialists undertaking care of patients with severe asthma. In this review, we provide an overview of the data supporting the clinical efficacy of biologics in distinct asthma phenotypes/endotypes. (Source: Respiratory Medicine)
Source: Respiratory Medicine - September 28, 2023 Category: Respiratory Medicine Authors: Linda Rogers, Milos Jesenak, Leif Bjermer, Nicola A. Hanania, Sven Seys, Zuzana Diamant Tags: Original Research Source Type: research
Reduced lung function and cause-specific mortality: A population-based study of Norwegian men followed for 26 years
Reduced lung function is associated with increased mortality, but it is unclear how different spirometric patterns are related to specific deaths. Aim of this study was to investigate these associations in a large general population cohort. (Source: Respiratory Medicine)
Source: Respiratory Medicine - September 28, 2023 Category: Respiratory Medicine Authors: Lucia Cestelli, Amund Gulsvik, Ane Johannessen, Knut Stavem, Rune Nielsen Tags: Original Research Source Type: research
Multiple bacterial culture positivity reflects the severity and prognosis as bronchiectasis in Mycobacterium avium complex pulmonary disease
Bacterial coinfections are observed in 19 –66% of patients with Mycobacterium avium complex pulmonary disease (MAC-PD) during the entire duration of the disease. The impact of bacterial coinfection at diagnosis on the clinical course of MAC-PD has not been reported. (Source: Respiratory Medicine)
Source: Respiratory Medicine - September 27, 2023 Category: Respiratory Medicine Authors: Masashi Ito, Koji Furuuchi, Keiji Fujiwara, Fumiya Watanabe, Tatsuya Kodama, Fumiko Uesugi, Yoshiaki Tanaka, Takashi Yoshiyama, Atsuyuki Kurashima, Ken Ohta, Kozo Morimoto Tags: Original Research Source Type: research
Severity of adult-onset asthma - a matter of blood neutrophils and severe obesity
Adult-onset asthma is associated with a poor treatment response. The aim was to study associations between clinical characteristics, asthma control and treatment in adult-onset asthma. (Source: Respiratory Medicine)
Source: Respiratory Medicine - September 26, 2023 Category: Respiratory Medicine Authors: Sofia Winsa-Lindmark, Caroline Stridsman, Axel Sahlin, Linnea Hedman, Nikolai Stenfors, Tomi Myrberg, Anne Lindberg, Eva R önmark, Helena Backman Tags: Original Research Source Type: research
Severity of adult onset-asthma-a matter of blood neutrophils and severe obesity
Adult-onset asthma is associated with a poor treatment response. The aim was to study associations between clinical characteristics, asthma control and treatment in adult-onset asthma. (Source: Respiratory Medicine)
Source: Respiratory Medicine - September 26, 2023 Category: Respiratory Medicine Authors: Sofia Winsa-Lindmark, Caroline Stridsman, Axel Sahlin, Linnea Hedman, Nikolai Stenfors, Tomi Myrberg, Anne Lindberg, Eva R önmark, Helena Backman Tags: Original Research Source Type: research
The perceived waning of biologics in severe asthma
Biologics are highly effective in severe asthma and used at fixed dosing intervals. However, in clinical practice, dosing intervals are sometimes shortened if patients perceive a decreased biologic effect before the next administration. The occurrence and clinical relevance of this perceived waning of biological effect is unknown. (Source: Respiratory Medicine)
Source: Respiratory Medicine - September 25, 2023 Category: Respiratory Medicine Authors: J.A. Kroes, L.H.G. Van Hal, L. Van Dijk, S.W. Zielhuis, A.N. Van Der Meer, E.N. Van Roon, A. Ten Brinke Tags: Original Research Source Type: research
Lung ultrasonography derived B-line scores as predictors of left ventricular end-diastolic pressure and pulmonary artery wedge pressure
Non-invasive assessment of elevated left ventricular end-diastolic pressure (LVEDP) and pulmonary artery wedge pressure (PAWP) in patients with heart diseases is challenging. Lung ultrasonography (LUS) is a promising modality for predicting LVEDP and PAWP. (Source: Respiratory Medicine)
Source: Respiratory Medicine - September 21, 2023 Category: Respiratory Medicine Authors: Marcos V.F. Garcia, Jonathan Wiesen, Siddharth Dugar, Jacob R. Adams, Corinne Bott-Silverman, Ajit Moghekar, Adriano R. Tonelli Tags: Original Research Source Type: research
Good COP or bad COP: How much steroid is enough to avoid relapse?
Organizing pneumonia (OP) is a lung disease steeped in contradictions. It is not common but nor can it be considered rare. It is grouped together with interstitial lung diseases, yet it is an abnormality of the airway and alveolar compartments. It is included under the rubric of acute lung injury, yet it typically follows a subacute course [1]. It can be triggered by conditions such as cancer and infection but also by their remedies such as radiation therapy and antibiotics [2]. Despite being associated with myriad causes, it is best known for its idiopathic version termed cryptogenic organizing pneumonia (COP). (Source: Respiratory Medicine)
Source: Respiratory Medicine - September 20, 2023 Category: Respiratory Medicine Authors: Oleg Epelbaum, Darren E. Gemoets Tags: Editorial Source Type: research
Pulse rate variability predicted cardiovascular disease in sleep disordered breathing: The Guangdong sleep health study
Pulse rate variability (PRV) predicts stroke in patients with sleep disordered breathing (SDB). However, the relationship between PRV and cardiovascular disease (CVD) was unknown in SDB. (Source: Respiratory Medicine)
Source: Respiratory Medicine - September 18, 2023 Category: Respiratory Medicine Authors: Miaochan Lao, Qiong Ou, Guangliang Shan, Murui Zheng, Guo Pei, Yanxia Xu, Longlong Wang, Jiaoying Tan, Bin Lu Tags: Original Research Source Type: research
Cell free ACE2 RNA: A potential biomarker of COVID-19 severity
Despite the downward trend of COVID-19 pandemic and increased immunity of the general population, COVID-19 is still an elusive disease with risks due to emerging variants. Fast and reliable diagnosis of COVID-19 disease would allow better therapeutic interventions for patients at risk to develop more severe outcomes. Cell-free RNAs (cfRNAs) have been proven to be an effective biomarker in cancer and infectious diseases. It has been reported that cfRNAs are amplified in the bloodstream of these patients and at earlier stages of the disease, reflecting tissue damage. (Source: Respiratory Medicine)
Source: Respiratory Medicine - September 18, 2023 Category: Respiratory Medicine Authors: Nour Jalaleddine, Mellissa Gaudet, Andrea Mogas, Mahmood Hachim, Abiola Senok, Narjes Saheb Sharif-Askari, Bassam Mahboub, Rabih Halwani, Qutayba Hamid, Saba Al Heialy Tags: Short communication Source Type: research
Burden of pulmonary hypertension due to chronic obstructive pulmonary disease: Analysis of exacerbations and healthcare resource utilization in the United States
The burden of pulmonary hypertension (PH) among patients with chronic obstructive pulmonary disease (COPD) is not well understood. The present retrospective cohort study aimed to quantify the clinical and economic burden of PH in patients with COPD. (Source: Respiratory Medicine)
Source: Respiratory Medicine - September 18, 2023 Category: Respiratory Medicine Authors: James R. Klinger, Benjamin Wu, Kellie Morland, Peter Classi, Ryan Fiano, Shannon Grabich Tags: Original Research Source Type: research
Palliative care interventions in chronic respiratory diseases: A systematic review
Chronic respiratory diseases represent a significant burden of disease globally, with high morbidity and mortality. Individuals living with these conditions, as well as their families, face considerable physical, emotional and social challenges. Palliative care might be a valuable approach to address their complex needs, but evidence to prove this is still scarce. (Source: Respiratory Medicine)
Source: Respiratory Medicine - September 15, 2023 Category: Respiratory Medicine Authors: Marta F é Santos, Paulo Reis-Pina Source Type: research
The spectrum of pulmonary amyloidosis
Amyloidosis is a disease caused by misfolded proteins that deposit in the extracellular matrix as fibrils, resulting in the dysfunction of the involved organ. The lung is a common target of Amyloidosis, but pulmonary amyloidosis is uncommonly diagnosed since it is rarely symptomatic. Diagnosis of pulmonary amyloidosis is usually made in the setting of systemic amyloidosis, however in cases of localized pulmonary disease, surgical or transbronchial tissue biopsy might be indicated. Pulmonary amyloidosis can be present in a variety of discrete entities. (Source: Respiratory Medicine)
Source: Respiratory Medicine - September 9, 2023 Category: Respiratory Medicine Authors: Anas Riehani, Ayman O. Soubani Source Type: research
Efficacy of inhaled tiotropium add-on to budesonide/formoterol in patients with bronchiolitis obliterans developing after hematopoietic stem cell transplantation
Bronchiolitis obliterans syndrome (BOS) is the lung manifestation of chronic graft-versus-host disease after hematopoietic stem cell transplantation (HSCT). We assessed whether inhaled tiotropium add-on to the combination regimen including budesonide/formoterol improve pulmonary function and the chronic obstructive pulmonary disease assessment test (CAT) scores in patients with BOS. (Source: Respiratory Medicine)
Source: Respiratory Medicine - September 9, 2023 Category: Respiratory Medicine Authors: Jeong Uk Lim, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chin Kook Rhee Tags: Original Research Source Type: research
Long-term clinical outcomes of elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis and advanced pulmonary disease
The combination of cystic fibrosis transmembrane conductance regulator (CFTR) modulators elexacaftor, tezacaftor and ivacaftor (ELX/TEZ/IVA) has been approved for treatment of cystic fibrosis (CF) patients (pwCF) homozygous and heterozygous for Phe508del. We aim to assess the long-term effects of ELX/TEZ/IVA therapy on clinical outcomes in severe pwCF. (Source: Respiratory Medicine)
Source: Respiratory Medicine - September 8, 2023 Category: Respiratory Medicine Authors: Daniela Savi, Francesca Lucca, Gloria Tridello, Ilaria Meneghelli, Isabella Comello, Sara Tomezzoli, Monica Signorini, Elena Proietti, Giulia Cucchetto, Sonia Volpi, Marco Cipolli Tags: Original Research Source Type: research
